OTCMKTS:PVCT Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis $0.07 0.00 (0.00%) As of 05/22/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock About Provectus Biopharmaceuticals Stock (OTCMKTS:PVCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PVCT alerts:Sign Up Key Stats Today's Range$0.07▼$0.0750-Day Range$0.05▼$0.0752-Week Range$0.04▼$0.11Volume91,554 shsAverage Volume184,158 shsMarket Capitalization$27.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Provectus Biopharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions. PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers. The therapy’s mechanism of action involves rapid, localized tumor cell destruction followed by the release of antigens that may enhance anti-tumor immunity. Provectus is pursuing regulatory filings and combination-therapy strategies aimed at broadening its clinical application and improving patient outcomes. Under the leadership of President and Chief Executive Officer Christine M. Locoh-Donou, Provectus has advanced its PV-10 clinical program through Phase 1/2 and pivotal studies, while also exploring strategic partnerships to support global development. The company maintains its operations in Tennessee and collaborates with research institutions and contract research organizations to drive its pipeline forward. Provectus continues to engage with regulatory authorities in North America and Asia-Pacific to secure marketing approvals and expand patient access. With a focus on single-agent and combination immunotherapies, the company aims to establish PV-10 as a versatile treatment option within the growing field of cancer immunotherapy.AI Generated. May Contain Errors. Read More Receive PVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PVCT Stock News HeadlinesProvectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study EndMay 18, 2026 | globenewswire.comHead to Head Analysis: Autolus Therapeutics (NASDAQ:AUTL) vs. Provectus Biopharmaceuticals (OTCMKTS:PVCT)May 17, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 25 at 1:00 AM | InvestorPlace (Ad)Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose ...May 4, 2026 | markets.businessinsider.comBascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus's VisiRose Subsidiary and Rose Bengal Sodium in Infectious KeratitisMay 4, 2026 | globenewswire.comProvectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, TennesseeApril 20, 2026 | globenewswire.comProvectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative ...April 2, 2026 | finance.yahoo.comProvectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue EnvironmentApril 2, 2026 | globenewswire.comSee More Headlines PVCT Stock Analysis - Frequently Asked Questions How have PVCT shares performed this year? Provectus Biopharmaceuticals' stock was trading at $0.0550 on January 1st, 2026. Since then, PVCT shares have increased by 18.2% and is now trading at $0.0650. How do I buy shares of Provectus Biopharmaceuticals? Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Provectus Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Provectus Biopharmaceuticals investors own include Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), American Superconductor (AMSC), Company Calendar Today5/25/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:PVCT Previous SymbolNYSEMKT:PVCT CIK315545 Webwww.provectusbio.com Phone(866) 594-5999Fax866-998-0005Employees4Year Founded2002Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.43 million Net MarginsN/A Pretax Margin-9,731.04% Return on EquityN/A Return on Assets-923.24% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.06 Sales & Book Value Annual Sales$340 thousand Price / Sales80.35 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-3.25Miscellaneous Outstanding Shares420,280,000Free Float358,499,000Market Cap$27.32 million OptionableNot Optionable Beta0.81 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (OTCMKTS:PVCT) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provectus Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
